Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 11, 2023

BUY
$0.39 - $0.71 $5,858 - $10,665
15,022 Added 6.17%
258,322 $107,000
Q4 2022

Feb 07, 2023

SELL
$0.33 - $10.44 $907 - $28,710
-2,750 Reduced 1.12%
243,300 $97,000
Q3 2022

Nov 14, 2022

BUY
$0.92 - $11.16 $183,034 - $2.22 Million
198,950 Added 422.4%
246,050 $209,000
Q2 2022

Jul 19, 2022

BUY
$1.02 - $1.83 $15,096 - $27,084
14,800 Added 45.82%
47,100 $54,000
Q1 2022

May 04, 2022

BUY
$1.06 - $2.1 $7,420 - $14,700
7,000 Added 27.67%
32,300 $45,000
Q4 2021

Jan 31, 2022

SELL
$2.05 - $3.2 $3,074 - $4,800
-1,500 Reduced 5.6%
25,300 $51,000
Q3 2021

Oct 29, 2021

SELL
$2.54 - $4.07 $17,145 - $27,472
-6,750 Reduced 20.12%
26,800 $82,000
Q2 2021

Aug 11, 2021

SELL
$2.57 - $4.85 $6,425 - $12,125
-2,500 Reduced 6.93%
33,550 $136,000
Q1 2021

May 04, 2021

SELL
$1.9 - $2.82 $9,500 - $14,100
-5,000 Reduced 12.18%
36,050 $89,000
Q4 2020

Feb 11, 2021

SELL
$1.15 - $2.4 $345 - $720
-300 Reduced 0.73%
41,050 $87,000
Q3 2020

Nov 05, 2020

BUY
$1.11 - $1.68 $2,220 - $3,360
2,000 Added 5.08%
41,350 $50,000
Q2 2020

Aug 12, 2020

BUY
$1.69 - $4.2 $36,335 - $90,300
21,500 Added 120.45%
39,350 $67,000
Q1 2020

May 11, 2020

SELL
$1.26 - $3.38 $15,926 - $42,723
-12,640 Reduced 41.46%
17,850 $47,000
Q4 2019

Feb 05, 2020

SELL
$0.86 - $1.44 $172 - $288
-200 Reduced 0.65%
30,490 $40,000
Q3 2019

Oct 30, 2019

BUY
$1.21 - $1.59 $4,831 - $6,348
3,993 Added 14.96%
30,690 $37,000
Q2 2019

Jul 19, 2019

BUY
$1.25 - $3.14 $10,067 - $25,289
8,054 Added 43.2%
26,697 $40,000
Q1 2019

May 13, 2019

BUY
$2.79 - $4.09 $17,936 - $26,294
6,429 Added 52.64%
18,643 $55,000
Q4 2018

Feb 11, 2019

SELL
$3.23 - $7.01 $15,210 - $33,010
-4,709 Reduced 27.83%
12,214 $41,000
Q3 2018

Nov 06, 2018

BUY
$6.86 - $9.97 $116,091 - $168,722
16,923 New
16,923 $122,000

Others Institutions Holding VSTM

About Verastem, Inc.


  • Ticker VSTM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 210,000,000
  • Market Cap $838M
  • Description
  • Verastem, Inc., a development-stage biopharmaceutical company, focusing on developing and commercializing drugs for the treatment of cancer. Its product in development includes VS-6766, a dual rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase (MEK) clamp that blocks MEK kinase activity and the ability of RAF to phosphorylat...
More about VSTM
Track This Portfolio

Track Commonwealth Equity Services, LLC Portfolio

Follow Commonwealth Equity Services, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Commonwealth Equity Services, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Commonwealth Equity Services, LLC with notifications on news.